Applied Materials, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Applied Materials, Inc. trades at $571.64 (market cap $478.36B), while State Street SPDR S&P Biotech ETF trades at $154.5. The key difference: Applied Materials, Inc. pays a 0.35% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Applied Materials, Inc. nearer its low. Which is the better fit depends on your goals.
| AMAT | XBI | |
|---|---|---|
Market Cap | $478.36B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $723.00 | $164.28 |
52-Week Low | $156.25 | $85.16 |
Enterprise Value | $477.39B | — |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
Applied Materials (AMAT) trades at $602.50, up 2.35% recently, with strong technical support near $573 and resistance at $617. The company demonstrates robust fundamentals, including a 29.31% net income margin and consistent earnings beats, while benefiting from AI-driven semiconductor demand highlighted in recent CEO commentary (CNBC, 2026-05-28).
Outlook remains positive given analyst consensus of $644.33 price target and 76.9% buy ratings, though elevated P/E of 56.68 poses valuation risk. Key opportunities include AI infrastructure growth, while risks involve cyclical semiconductor demand and execution challenges in scaling operations.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Applied Materials is the world's largest supplier of semiconductor manufacturing equipment, providing materials engineering solutions to help make nearly every chip in the world. The firm's systems are used in nearly every major process step with the exception of lithography. Key tools include those for chemical and physical vapor deposition, etching, chemical mechanical polishing, wafer- and reticle-inspection, critical dimension measurement, and defect-inspection scanning electron microscopes.
Read more on AMAT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →